4.5 mg tirzepatide 5mg Tirz 5 mg – Gila

In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them

Sci Rep 6:30088

Improper storage of GLP-1 medications can compromise their therapeutic effectiveness and safety

Fine lines soften Collagen production takes time to rebuild

Retatrutide is emerging as a multi-pathway, short-protein therapeutic with potential benefits that reach into metabolic health, visceral fat reduction, and possibly even longevity